Novartis to acquire Tourmaline Bio for $1.4 billion
MLex Summary: Switzerland-based Novartis AG plans to acquire New York-based Tourmaline Bio, a late-stage clinical biotech company focusing on inflammatory and immune diseases. The deal, valued at approximately $1.4 billion, is expected...To view the full article, register now.
Already a subscriber? Click here to view full article